STAR Pharmaceutical Limited reported unaudited group earnings results for the second quarter and six months ended June 30, 2018. For the quarter, the company reported Revenue was RMB 37,154,000 against RMB 17,570,000 for the same period a year ago. Loss from operations of RMB 996,000, profit before income tax of RMB 1,611,000, profit attributable to equity holders of the parent was RMB 3,122,000 or 6.72 cents per basic and diluted share against profit from operations of RMB 3,251,000, profit before income tax of RMB 2,020,000, profit attributable to equity holders of the parent was RMB 1,305,000 or 2.80 cents per basic and diluted share a year ago. Net cash generated from operating activities was RMB 5,573,000 against RMB 5,008,000 for the same period a year ago. Purchase of property, plant and equipment was RMB 115,000 against RMB 245,000 for the same period a year ago. Group revenue increased 111% from the same period a year ago, due to higher sales of Antibiotics, Cardiovasular drugs and Cerebovascular drugs and other specialized drugs. For the six months, the company reported Revenue was RMB 104,606,000 against RMB 37,461,000 for the same period a year ago. Profit from operations of RMB 8,356,000, profit before income tax of RMB 9,032,000, profit attributable to equity holders of the parent was RMB 9,995,000 or 21.50 cents per basic and diluted share against profit from operations of RMB 8,204,000, profit before income tax of RMB 6,608,000, profit attributable to equity holders of the parent was RMB 5,240,000 or 11.24 cents per basic and diluted share a year ago. Net cash generated from operating activities was RMB 11,275,000 against RMB 14,265,000 for the same period a year ago. Purchase of property, plant and equipment was RMB 158,000 against RMB 3,021,000 for the same period a year ago. Net asset value per ordinary share capital at the end of the period was 311.3 cents.